Exposure to hydralazine contributed to the development of ANCA-associated vasculitis through the formation of hydrazone adducts on myeloperoxidase, which alter its structure and promote autoimmunity. Read more: https://bit.ly/3XV5tfd #RareDisease
Rare Disease Advisor
Book and Periodical Publishing
Rare Disease Advisor is a dedicated resource for healthcare professionals to better understand and diagnose rare disease
About us
Rare Disease Advisor is an online resource for health care professionals who treat patients with rare diseases. Company Overview Haymarket Media offers a wide range of authoritative publications and services for the professional medical community. Rare Disease Advisor is an online resource that provides health care professionals with comprehensive information on important principles of care in rare diseases as well as up-to-date clinical news on the diagnosis and treatment of these conditions. Website features include: • Daily news • Feature articles on key issues in rare disease • Live conference coverage • Expert opinion articles, including exclusive guest editorials from leading rare disease experts • Concise drug monographs • Medical slideshows • Videos • Continuing medical education (CME) activities • And more...
- Website
-
https://www.rarediseaseadvisor.com/
External link for Rare Disease Advisor
- Industry
- Book and Periodical Publishing
- Company size
- 11-50 employees
- Type
- Privately Held
- Specialties
- Rare Disease, Pompe Disease, Alagille Syndrome, Neuromyelitis Optica Spectrum Disorder, Pulmonary Arterial Hypertension , Cold Agglutinin Disease, Spinal Muscular Atrophy, Duchenne Muscular Dystrophy, Hemophilia, Sickle Cell Disease, Myasthenia Gravis, Long Chain Fatty Acid Oxidation Disorder, Gastrointestinal Stromal Tumor, Lysosomal Acid Lipase Deficiency, Multiple Sclerosis , Cholangiocarcinoma, Medullary Thyroid Carcinoma , Alpha-1 Antitrypsin Deficiency, Cystic Fibrosis , Idiopathic Pulmonary Fibrosis, Systemic Mastocytosis, Hereditary Angioedema, Hereditary Transthyretin Amyloidosis, Diffuse Large B-Cell Lymphoma, Huntington Disease, and Wilson Disease
Employees at Rare Disease Advisor
-
Thomas Bartlett
Speaker - DHAI 2024 Patients and AI, WODC 2025 AI impact on Patients/Myasthenia Gravis Patient Advocate/Myasthenia Gravis Patient Digital Technology…
-
Juliette Siegfried, MPH
Director, Medical Editing, Writing, and Journalism
-
Özge Özkaya
Science Writer at Rare Disease Advisor
-
Tara Keith
Freelance Writer
Updates
-
Tisagenlecleucel, a CD19 CAR T-cell therapy, showed durable efficacy and improved safety in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma compared to previous trial data. Read more: https://bit.ly/41nOWS2 #MedNews #Oncology
-
Retinal dysfunction in NMOSD may stem from Müller cell activation by IgG antibodies, according to a Journal of Neuroinflammation study. This triggers complement 3 secretion, activating microglia. Read more: https://bit.ly/4hBH1GG #MedNews
-
An evidence-based checklist has been developed that is intended for use by caregivers of newborns in the NICU in cases of preterm birth, including among those with hemolytic disease of the fetus and newborn (#HDFN). Read more: https://bit.ly/41x233t #MedNews
-
Rare Disease Advisor reposted this
#WorldOrphanUSA is excited to introduce our 2025 Supporting Partner – Rare Disease Advisor! Rare Disease Advisor (RDA) is a leading online resource for healthcare providers who treat #rarediseases. RDA publishes timely news, exclusive features, expert opinions, and valuable resources across 40+ rare disease areas with the goal of helping reduce the time to #diagnosis for the diseases they cover, while also keeping care teams up to date on the latest advancements in diagnosis and treatment. 🗞️🦠💡 The World Orphan Drug Congress USA is proud to support RDA's commitment to empowering patients, caregivers, and industry professionals. Join RDA and hundreds of rare disease professionals next month in Boston to accelerate treatments, expand access, and change lives for those living with rare diseases. 🎟️ 𝐆𝐞𝐭 𝐲𝐨𝐮𝐫 𝐝𝐢𝐬𝐜𝐨𝐮𝐧𝐭𝐞𝐝 𝐭𝐢𝐜𝐤𝐞𝐭 𝐛𝐞𝐥𝐨𝐰 & 𝐬𝐞𝐜𝐮𝐫𝐞 𝐲𝐨𝐮𝐫 𝐬𝐩𝐨𝐭 ↴ 60% off pharma & biotech passes expires tomorrow ★ Book now with code RARE60 & save BIG ➤ https://lnkd.in/eaz-cxwZ Final early-bird tickets available ★ Plus, book your group and save up to 50% today ➤ https://lnkd.in/eaz-cxwZ Just 30 free VIP passes remain ★ Patient advocates & hospital practitioners, secure your FREE pass now before they're gone ➤ https://lnkd.in/ezqcD2G4
-
-
#Achondroplasia, the most common short-statured skeletal dysplasia, is associated with increased mental health concerns, pain, and functional limitations that collectively impair health-related quality of life. 📚 Orphanet Read more: https://bit.ly/3XTsKy9 #RareDisease
-
COVID-19 had a greater effect on the mental health of patients with chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy than patients with motor neuron disease, according to a study in Frontiers in Neurology. Read more: https://bit.ly/4bWpEiH #MedNews #CIDP
-
A case involving a newborn with thrombocytopenia illustrated the importance of considering all possible fetal and neonatal alloimmune thrombocytopenia (#FNAIT) differential diagnoses, including hemophagocytic lymphohistiocytosis. Read more: https://bit.ly/3R5hJ97 #CaseReport
-
#MDAConference: "For adults with DMD—this is based on my experience and others with DMD—the biggest challenge we have with going from pediatric to adult care is missing out on all the benefits from multidisciplinary clinics where all our information is in the same place." - Tyus Hill, an adult patient diagnosed with Duchenne muscular dystrophy, during the session "Navigating Transition: Strategies for Care Across Settings and Life Stages." Muscular Dystrophy Association #RDAatMDA
-
-
A new Clinical Global Impression of Improvement (CGI-I) measure was developed to assess non-seizure symptoms in Lennox-Gastaut and Dravet syndromes, according to the Journal of Patient-Reported Outcomes. Read more: https://bit.ly/4kNtKxC #MedNews